Aug. 19 at 8:13 PM
$HALO Still no capitulation by the Goldman Sachs’ Corrine Johnson. She still has a sell rating with price target of
$57 which she issued when Halozyme was trading in
$60’s. That was likely the most comical rating of the year in the entire biopharma industry.
Considering this lack of capitulation and the fact that the forward PE for Halozyme is still in low teens, don’t be surprised if we continue to climb.
